Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin

BACKGROUND: Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these drugs in BRCA1-driven high-grade serous ovarian carcinomas (HGSOCs). METHODS: Ten HGSOC patients with germ-line BRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorodnova, Tatiana V., Sokolenko, Anna P., Kotiv, Khristina B., Sokolova, Tatiana N., Ivantsov, Alexandr O., Guseynov, Konstantin D., Nekrasova, Ekaterina A., Smirnova, Olga A., Berlev, Igor V., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860626/
https://www.ncbi.nlm.nih.gov/pubmed/33536037
http://dx.doi.org/10.1186/s13053-021-00173-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860626/
https://www.ncbi.nlm.nih.gov/pubmed/33536037
http://dx.doi.org/10.1186/s13053-021-00173-2

Ejemplares similares